Barbara Weber, M.D.
Barbara Weber joined Third Rock Ventures in 2015 to focus on oncology research and development opportunities throughout the portfolio.
- Interim chief executive officer of Tango Therapeutics
Barbara brings over 25 years of experience working in oncology research, in which time she has been widely published and received numerous academic and research awards for her work. Barbara has spent the last six years at Novartis, where she held the position of senior vice president and global head of oncology translational medicine. In this role, she was responsible for early clinical and translational scientific functions, including trial design and execution, implementation of patient selection strategies and continuation of translational support through full development. Prior to joining Novartis, Barbara served as vice president of three groups at GlaxoSmithKline, including Global Biomarkers, Oncology Discovery and Translational Medicine, and Cancer Metabolism Drug Discovery. Until 2005, Barbara was a professor of medicine and genetics at The University of Pennsylvania School of Medicine, heading a clinical and translational research program in cancer genetics and the UPenn Cancer Center Breast Cancer program. Barbara is a member of honorary societies such as the American Association of Physicians and the American Society for Clinical Investigation, of which she served as President in 2005. Barbara has also served on various scientific advisory boards and on the board of directors of both the American Society of Clinical Oncology and the American Association of Cancer Research. Barbara is a graduate of the University of Washington School of Medicine. She completed her residency in internal medicine at Yale University School of Medicine and her fellowship in medical oncology at the Dana-Farber Cancer Institute.
Barbara has received two standing ovations in her life – most notably from an entire restaurant after eating every bite of an apple pie.